NCT06252649Phase 3Listed as recruiting
Untreated metastatic colorectal cancer with a KRAS G12C mutation: sotorasib and panitumumab added to chemotherapy
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Minimum age: 18 years
Centres in: București · Cluj-Napoca · Craiova · and 3 more cities
See all centres (7)Hide the centre list
These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.
Central study contact
To find the team and exact institution in your chosen city, quote study NCT06252649. This contact may be in another country; ask which language you can use.
Source: study registry
We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.
București
Institutul Clinic Fundeni
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Cluj-Napoca
Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Craiova
Centrul de Oncologie Sf Nectarie SRL
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Iași
Institutul Regional de Oncologie Iasi
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Ploiești
Spitalul Municipal Ploiesti
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Timișoara
SC Oncomed SRL
The registry does not publish a local contact with a usable phone number or email address. Ask the central contact above for the centre's details
Search the directory for contact details ↗ (new tab)
Who can take part
Untreated metastatic colorectal cancer with a KRAS G12C mutation: sotorasib and panitumumab added to chemotherapy
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
- Minimum age:
- 18 years
- Maximum age:
- Not specified in the record consulted
- Participant sex, as recorded in the registry:
- All sexes
This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.
Criteria published in the registry — English original
Inclusion Criteria: * Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay. * Central laboratory detection of KRAS p.G12C mutation. * Measurable metastatic disease per RECIST v1.1 criteria. * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1. * Adequate organ function. Exclusion Criteria: * Active, untreated brain metastases. * Leptomeningeal disease * Previous treatment with a KRAS p.G12C inhibitor * History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan
What taking part involves
Participants are randomly assigned to the study groups.
These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.
Group 1 · Studied intervention
FOLFIRI Regimen · Sotorasib · Panitumumab
Group 2 · Active treatment comparison
FOLFIRI Regimen · Bevacizumab-awwb
- Start of the whole study
- 17 July 2024
- Completion of the whole study
- 25 April 2032 (estimated)
These are global study dates, not an individual's participation duration or an enrolment deadline.
Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.
Ask the study team before travelling:
- whether places are available at the chosen centre and how the first assessment is arranged
- how often you need to attend the centre and whether a hospital stay is necessary
- whether travel or accommodation costs are covered and under what conditions
- which documents you need to prepare and whether a family member or carer can accompany you
Original registry title
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Updated in the registry: 3 September 2026
Data consulted: 19 November 2026
See the official record ↗If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.
